Early gluten-challenge clinical results are sharpening attention on dosing strategies for CD122-targeting therapies in celiac disease. The report highlights Phase I readouts for First Tracks Biotherapeutics’ CD122 antibody (ANB033), which met primary and key secondary endpoints in a placebo-controlled study, adding momentum to this mechanism even as analysts compare it against alternatives.